A 2023 study in Diabetes Care noted that GLP-1 agonists reduce systemic inflammation markers in patients with metabolic syndrome
GLP-1 is FDA-approved as Wegovy for chronic weight management in individuals with or without diabetes, says Dr
PlexusDx serves all 50 states without insurance requirements, meaning patients access prescribers regardless of employer health plans or insurance status
Marek-Iannucci S, Ozdemir AB, Moreira D, Gomez AC, Lane M, Porritt RA, et al
Convincing improvement in OA In a 2024 paper published in T he New England Journal of Medicine, Bliddal and colleagues enrolled 407 patients with knee OA and obesity in a double-blind, randomized, placebo-controlled trial, called STEP-9, at 61 sites across 11 countries
Differences between two groups were assessed using Students t -test or AspinWelch t test, followed by Bonferronis correction for comparing multiple time points vs